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Abstract 
Manipulation of gene expression is an invaluable tool to study gene function in vitro 
and in vivo. The application of small inhibitory RNAs to knock down gene expression 
provides a relatively simple, elegant, but transient approach to study gene function in many 
cell types as well as in whole animals. Short hairpin structures (sh-RNAs) are a logical 
advance as they can be expressed continuously and are hence suitable for stable gene 
knockdown.  Drug-inducible systems have now been developed; however, application of the 
technology has been hampered by persistent problems with low or transient expression, 
leakiness or poor inducibility of the short hairpin and lack of reversibility. We have 
developed a robust, versatile, single lentiviral vector tool that delivers tightly regulated, fully 
reversible, Doxycyline- responsive knockdown of target genes (FOXP3 and MYB) using 
single short hairpin RNAs.  To demonstrate the capabilities of the vector we targeted FOXP3 
because it plays a critical role in the development and function of regulatory T cells. We also 
targeted MYB because of its essential role in haematopoiesis and implication in breast cancer 
progression. The versatility of this vector is hence demonstrated by knockdown of distinct 
genes in two biologically separate systems. 
Introduction  
Conditional gene knockdown is a powerful tool both to study gene function and as a 
potential therapeutic. Systems for achieving this are constantly evolving. Short hairpin RNAs 
(shRNAs) provide an elegant and relatively straightforward approach for post-transcriptional 
down regulation of gene expression [1], because unlike siRNA these can be stably expressed 
within the cell, and  are not lost with cell division. Drug-inducible activation of short hairpin 
RNAs provide a more finely tuned approach to gene knockdown, avoiding the artefacts that 
may result from constitutive gene knockdown [2]. There are still problems however in 
achieving effective and regulated knock-down by sh-RNAs, associated particularly with poor 
inducibility of the short hairpin[3], insufficient transcriptional activity of cell specific 
promoters [4], self-targeting of the shRNA sequence [5, 6], transient knockdown of the target 
gene, leakiness of short hairpin activity in the un-induced state [7, 8] and lack of reversibility 
[9].   
Lentiviral vectors are an appealing vehicle with which to deliver genes or shRNAs, 
particularly because they are capable of transducing most non-dividing or quiescent cells 
[10].  This is important for transfer into haematopoietic cells or other primary human cell 
types which are typically refractory to transfection and transduce inefficiently with other 
virus types [11-13]. In addition, lentiviral vectors offer several advantages over other viral 
vectors: they are more efficient at delivering complex gene expression cassettes compared 
with other retroviral vectors [14], they can mediate long term gene expression [15] and are 
relatively safe.   
The biological targets used to validate the vectors for this study were chosen as they are of 
clinical significance in autoimmunity and cancer. In the first example we focussed on the 
transcription factor FOXP3, the master transcription factor of regulatory T cells. Regulatory 
T cells (Tregs) are essential for normal immune homeostasis, balancing prevention of 
autoimmunity and immune pathology on the one hand, whilst simultaneously allowing 
effective immunity to infection and tumours on the other. Many now regard these cells as 
“master regulators” of immune responsiveness[16]. The forkhead transcription factor, 
FOXP3, is expressed constitutively in „natural‟ CD4+ Treg cells and has been shown to be 
necessary and sufficient for mouse Treg cell function [17-19] [20, 21]. Less is known about 
the role human FOXP3 plays in the development and function of the Treg cell (reviewed by 
[22]). 
  In order to demonstrate the robustness of the vector, we also chose a second target, 
the MYB oncogene, which encodes a transcription factor (MYB). MYB is predominantly 
associated with normal and leukemic haematopoiesis based on its pattern of expression [23, 
24] the consequences of loss of expression [25] [26] and its ability to induce leukemogenesis 
in several species (reviewed in [27]).  MYB is also expressed at relatively high levels in at 
least two epithelial tumors: colon [28] and breast cancer [29]. Evidence of a causal role in 
carcinogenesis includes the correlation of expression level with poor prognosis [30] and the 
presence of mutations that are likely to dysregulate MYB expression [31, 32].  
We describe here a lentiviral system able to knockdown target genes reversibly using 
Doxycycline (Dox) induction. This system differs from previously described vectors as it 
combines exquisite sensitivity to Dox with very fast kinetics, efficient induction of shRNA 
expression and reversibility in a single lenti-vector. Vectors described in prior work [2, 7, 8, 
33, 34] do not combine all of these characteristics in a single vector. We have used two 
biologically distinct systems to model the robust gene silencing capability of this vector. 
Materials and Methods  
Vector construction 
The third generation lentiviral vectors containing the human hepatitis virus PRE element and 
the HIV cPPT element (described in Barry et al) were used for all experiments.  For gene 
over expression the backbone was re-engineered to contain the elongation factor 1alpha  
promoter (plvEIG), a gateway cloning site (att, CAT ccdB att), and an IRES to drive the 
marker gene (GFP).  To generate the shRNAi delivery vector (plvTsh), this backbone was 
engineered to contain a gateway cassette (att, CAT ccdB att) upstream of the rev responsive 
element into which the shRNAi cassette is recombined. The regulatory protein (Trex™) was 
inserted under the control of the EF1alpha promoter, and the marker gene (GFP) is expressed 
from an IRES. 
 
Short hairpin expression constructs 
Five short hairpin (sh-RNA) sequences predicted to knockdown FOXP3 expression were 
designed using BLOCK-iT™ RNAi Designer (Invitrogen Corp. Carlsbad, CA, USA). The 
following FOXP3 sequences were chosen as potential shRNA targets and were numbered 






Using the above target sequences, sh-RNA constructs were generated in a sense-loop-
antisense expression format, using a 9 mer: TTCATGAGA to form the loop. A 3-step PCR 
procedure was used to generate the shRNA targeting sequences. PCR primers were designed 
to generate 2 PCR products: a 5′end with the attB1 site, tH1 promoter, sense strand of the 
stem structure and the loop, and a 3′ end with the loop, antisense strand of the stem structure, 
termination signal and attB2 site. In step 1, a 5′ PCR product was generated using pBS-tH1, 
containing the tet-H1 promoter as template DNA, an attB1 forward primer and a site-specific 
reverse primer (see below for primer sequences). In step 2, a 3′ PCR product was generated 
using a site-specific forward primer and an attB2 reverse primer (see below for primer 
sequences). In this reaction the forward and reverse primers overlap and no template DNA 
was required. Products from these two reactions were subsequently gel purified (Qiaquick 
Gel Extraction Kit, Qiagen GmbH, Germany), quantitated, combined and used as the 
template in a third PCR reaction using the attB1 forward primer and the attB2 reverse primer. 
The final PCR product was gel purified and inserted into the pDonr107 entry vector as 
described below. 
 
 Forward (5’) and Reverse (3’) Primers used to generate shRNAs: 
attB1 Forward Primer: GGGGACAAGTTTGTACAAAAAAGCAGGCTT 
attB2 Reverse Primer: GGGGACCACTTTGTACAAGAAAGCTGGGTA 
1355 Forward Primer: TGTTTCATGAGAACAAAGCACTTGTGCAGA 
1355 Reverse Primer: TGTTCTCATGAAACAAAGCACTTGTGCAGA 
485 Forward Primer: GCTTTCATGAGAAGCTGGTGCATGAAATGT 
485 Reverse Primer: GCTTCTCATGAAAGCTGGTGCATGAAATGT 
1289 Forward Primer: GAATTCATGAGAAAGACTTCTTCCGTTTGT 
1289 Reverse Primer: GAATCTCATGAAAAGACTTCTTCCGTTTGT 
767 Forward Primer: CAATCTCATGAATTGCAGACACCATTTGCC 
767 Reverse Primer: CAATTCATGAGATTGCAGACACCATTTGCC 
981 Forward Primer: TCTTTCATGAGAAGATGAAGCCTTGGTCAG 
981 Reverse Primer: TCTTGTCATGAAAGATGAAGCCTTGGTCAG 
The Gateway® Technology (Invitrogen Corp.) universal cloning system was used for the 
transfer of short hairpin expression cassettes (FOXP3 and sh-β-Catenin) and FOXP3 cDNA 
into expression vectors. Short hairpin cassettes were inserted into a Gateway® (Invitrogen 
Corp.) compatible entry vector (pDonr) using Gateway® BP clonase recombination 
techniques and transferred from the entry clone to the Gateway® (Invitrogen Corp.) 
compatible lentiviral destination vector (plv), using Gateway® LR clonase recombination 
techniques. FOXP3 lentiviral expression vectors were generated in a similar fashion, 
inserting FOXP3 cDNA into lentiviral destination vector plvEIG.  All constructs were 
sequenced (Big Dye® Terminator Cycle Sequencing Kit v3.1, Applied Biosystems) prior to 
use in experiments. 
 
Cell Culture 
HEK293T cells were routinely cultured in D-MEM (Gibco, Invitrogen), 10% FCS (JRH 
Biosciences Inc. Lenoxa, KA, USA), 1% pen/strep, 1% L-Glutamine, and used between 
passage 11-20. Jurkat cells were routinely cultured in RPMI (SAFC Biosciences, Lenoxa, 
KA,USA), 10% FCS (JRH Biosciences Inc. Lenoxa, KA, USA), 1% pen/strep, 1% L-
Glutamine and used between passage 15-20. For transient transfection of cells for Dual 
Luciferase® Reporter Assays, HEK293T cells were seeded at a density of 1x10
5
 cells in 
500µl of medium (DMEM/10%FCS/1% pen/strep, 1% L-Glutamine) in a 24 well plate and 
transiently transfected with 25ng psi-check2™ vector and 775ng shRNA vector 4hr later 
using Lipofectamine™ 2000 reagent (Invitrogen Corp.) and Opti-MEM® (Invitrogen Corp) 
reduced serum medium, following the standard protocol. For transient transfection of Jurkat 
cells for Dual Luciferase® Reporter Assays, cells were seeded similarly in 500µl of medium 
(RPMI 10%FCS/1% pen/strep 1% L-Glutamine) and transiently transfected using 
Lipofectamine™ LTX reagent (Invitrogen Corp.) using Opti-MEM® (Invitrogen Corp) 
reduced serum medium. All transfections were carried out in triplicates. 
MCF7 cells, a human transformed malignant breast cancer line, cultured in RPMI transduced 
with the shMyb or shSCR scrambled trigger sequences were generated using the same 
protocols as described in [35]. GFP+ve cells were enriched by cell sorting.  Transduced cells 
were cultured in the presence or absence of Dox (1µg/ml) for 48 hr unless otherwise stated.  
 
Isolation and in vitro expansion of cord blood T cell populations 
Cord blood was obtained with informed maternal consent as approved by the Children's, 
Youth and Women's Health Service Research Ethics Committee. Mononuclear cells (MNC) 
were isolated from 60-100ml venous blood collected directly post partum into pre-weighed 
blood collection bags (Fenwell) containing anticoagulant as previously described [36]. Cord 
blood CD4+ CD25+ (Treg) and CD4+ CD25- (Thelper) cells were isolated from MNC using 
a Dynabeads Regulatory CD4+CD25+ T cell kit (Invitrogen). The purity for each cell type 
was routinely greater than 90% by two colour flow cytomety for CD4 and CD25 expression. 
Cells were routinely expanded for 8 days in the presence of Dynabeads CD3/CD28 T cell 
expander beads (Invitrogen; Cat# 111-41D) at a bead to cell ratio of 3:1, prior to magnetic 
removal of the beads. Ex vivo expansion of isolated T cell populations (1x10
6
 cells/well in a 
24 well plate) were performed in X-Vivo 15 media (BioWhitticker) supplemented with 
20mM HEPES-, pH 7.4, 5% heat inactivated pooled human serum (Lonza), 2mM l-glutamine 
and 500U/ml recombinant human interleukin-2 (rhIL2; R&D research)  
 
 Proliferation assays 
MCF7 cells previously transduced with plv-T-sh-Myb or plv-T-sh-SCR were cultured in 
triplicate in the presence or absence of Dox for 12 days. Cell proliferation was measure by 
cell counting using a Coulter counter. Replicate samples were also treated to washout the 
Dox from day 5. In one group of replicates of the sh-Myb transduced cells, Dox was washed 




For generating lentiviral stocks, HEK293T cells were seeded at a density of 6x10
6
 cells in 
18ml medium in a 75cm
2
 tissue culture flask. Cells were transfected with 12.5 µg transfer 
vector (pvlEIG), 7.5 µg Gag/Pol (∆ 8.2), 6.25 µg Rev  (pRSV-Rev), 3.75 µg Env (pCMV-
VSV-G) using Lipofectamine™ 2000 reagent (Invitrogen) and using Opti-MEM® 
(Invitrogen Corp) reduced serum medium, following the standard protocol. The following 
day, the medium was replaced with 10ml fresh D-MEM and 48hr later supernatant was 
collected, filtered (0.45m) and used immediately or stored frozen (-70oC).  Virus was 
concentrated by unltracentrifugation at 22,000RPM for 90min at 4°C. The supernatant was 
aspirated and the pellet resuspended in 1/25 vol/vol of X vivo medium to give a 25x 
concentrated stock. Virus was titred by limiting dilution, as described previously [12]. 




 transducing units per ml 
 
Lentiviral Transduction 
For transduction of cell lines, cells were routinely seeded at a density of 3x10
5
 cells per well 
in a 6 well plate. Medium was replaced with 3ml viral supernatant (unconcentrated) 
containing polybrene at a final concentration of 5 µg/ml. GFP positive cells were sorted by 







T reg cells were transduced with lentivirus at a multiplicity of infection  
(MOI) of  approximately 20 24-48hr after isolation. Cells were expanded for 8 days in the 





 cells by flow cytometry.  
 
Intracellular staining 
For detection of FOXP3 expression, cells (1x10
5
) were washed in flow cytometry staining 
buffer (0.1% sodium azide, 1% FCS, in  phosphate buffered saline) and stained intracellularly 
with phycoerythrin- (PE) conjugated anti-human FOXP3 antibody (PCH101, eBioscience, 
Inc) using fixation/permeabilisation and permeabilisation reagents (eBioscience, Inc) and 
standard protocols. Cells were resuspended in fixation buffer (1% formaldehyde, 2% glucose, 
0.02% sodium azide in phosphate buffered saline) and analysed by flow cytometry (Beckman 
Coulter FACSCalibur). 
 
Purification of DNA and RNA 
DNA was prepared using Qiaprep® Spin Miniprep Kit (Qiagen GmbH, Germany) and 
HiSpeed® Plasmid Midi Purification Kit (Qiagen GmbH, Germany). RNA was prepared 
using miRNeasy mini kit (Qiagen GmbH, Germany). 
 
Analysis of RNA expression by real-time PCR  
RNA was reverse transcribed by Quantitect RT kit (Qiagen) Real Time PCR (RT-PCR) was 
performed on a Rotor-Gene 6000 (Corbett) using FastStart Taq DNA polymerase kit (Roche) 
and SYBR Green fluorescent dye. Transcription factor mRNA expression profiling was 
performed at various time points as described in the figure legends, and cells were analysed 
for relative abundance of FOXP3 compared to an internal control (Beta Actin).  
FOXP3F:  GAA ACA GCA CAT TCC CAG AGT TC 
 
FOXP3R:  ATG GCC CAG CGG ATG AG 
 
Beta Actin F: AAG AGC TAC GAG CTG CCT GAC 
 
Beta Actin R:  GTA GTT TCG TGG ATG CCA CAG 
 
Stem-loop Reverse Transcription-Polymerase Chain Reaction (SL-RT-PCR) 
Reverse transcriptase (RT) reactions were performed on 150ng of total RNA. First strand 
complementary DNA (cDNA) was synthesized using 0.05M of stem loop primer (SL-sh1355) 
(5‟-GTTGGCTCTGGTAGGATGCCGCTCTCAGGGCATCCTACCAGAGCCAACACAAAG-3‟), 
2M of antisense primer for the reference gene hypoxanthine phosphoribosyltransferase 
(Hprt-1) (5‟-CAGGCAAGACGTTCAGTCCT-3‟) using the SuperscriptTM III Reverse 
Transcriptase Kit (Invitrogen) according to manufacturer‟s protocol. SL-sh1355 contains a 
binding site for a universal reverse primer (URevP; 5‟-GTAGGATGCCGCTCTCAGG-3‟), a 
binding site for a Universal Probe Library (UPL) probe #21 (Roche Diagnostics) and a six 
base 3‟ overhang sequence, which is complementary to the last six bases at the 3‟ end of 
sh1355. Pulse RT was carried out using previously described conditions with modifications 
[37, 38]. Briefly, RNA was initially incubated at 65
o
C for 5 minutes to uncoil the RNA. 
cDNA synthesis was then performed at 16
o
C for 30 minutes followed by 60 cycles of 20
o
C 
for 30 seconds, 42
o
C for 30 seconds and 50
o
C for 1 second. Final incubation at 75
o
C for 15 
minutes was performed to inactivate the reaction. Additional RT minus (without reverse 
transcriptase) reactions served as negative control. For quantitative PCR, a 20l reaction 
containing 0.005x synthesized cDNA (from either RT positive or minus reaction), 1x LC480 
Master Probe Mix (Roche Diagnostics), 250nM of forward (sh1355 forward primer 5‟-
CGGCCGAGTCTGCACAAGTG-3‟, Hprt-1 forward primer 5‟-
TGACCTTGATTATTTTGCATACC-3‟) and reverse primers (URevP, Hprt antisense  
primers) (GeneWorks Pty Ltd, Aus.), and 100nM of UPL probe #21 (for sh1355), #73 (for 
Hprt1) (Roche Diagnostics), was prepared for each sample. PCR reactions were performed 
using the LightCycler® 480 System (Roche Diagnostics) with a pre-denaturing step of 95
o
C 
for 10 minutes, and 45 cycles of 95
o
C (10 seconds), 60
o
C (30 seconds) and 72
o
C (10 seconds) 
followed by a cooling step at 40
o
C for 1 minute. Semi-quantitative PCR was performed using 
the exact reaction setup and conditions for only 34-36 cycles without the presence of UPL 
probe. Cycle threshold value (Ct) was calculated from the amplification curve using Second 
Derivative Maximum method [39] provided in LightCycler® 480 Quantification Software 
version 1.5 (Roche). To compare the Ct value with gel electrophoresis results, we normalized 
the value to Hprt-1 using the comparative Ct method. 
 
Dual Luciferase® Reporter Assays. 
For luciferase assays, FOXP3 and β-Catenin cDNAs were inserted into the multi-cloning site 
of psiCHECK™-2 (Promega Corp. Madison, WI) vector. PsiCHECK™-2 is a dual luciferase 
reporter construct in which the cDNA of interest is cloned into the 3`UTR of the Renilla 
luciferase gene. Renilla luciferase activity is normalised with respect to Firefly luciferase 
activity, which is carried on the same vector to control for transfection efficiency.   All 
constructs were sequenced (Big Dye® Terminator Cycle Sequencing Kit v3.1, Applied 
Biosystems) prior to use in experiments. Cells were transiently transfected as described 
above, before incubation in the absence or presence of Doxycyline (1µg/ml). Subsequently, 
culture medium was removed and cells were lysed using Dual Luciferase® Reporter Assay 
reagents (Promega Corp Madison, WI) following the standard protocol. Samples were 
assayed using Luciferase Assay Reagent II (LAR II) and Stop & Glo® reagents and analysed 
using a Veritas Micro Plate Luminometer (Turner Biosystems). 
Results 
A single lentiviral vector to conditionally knockdown gene expression.  
A lentiviral vector was designed to achieve tightly regulated, drug inducible knockdown of 
target gene expression. Short hairpin RNA expression cassettes generated by PCR are 
inserted into the expression vector via donor vector intermediaries using Gateway® 
technology. The shRNA sequence is expressed from the tet operator-H1 promoter fusion 
(tH1) in either donor vectors for validation, (pDONR) or transfer vectors for lentiviral 
delivery (plv-T-sh). The TRex repressor cassette transcribed from an EF1α promoter is 
included in the LV backbone thereby delivering all the components required for tetracycline-
induced de-repression of sh-RNA transcription in one vector. An internal ribosome entry site 
(IRES) downstream of the TRex cassette is inserted for expression of the marker gene GFP 
(Fig. 1a).  
 
 Cloning and screening of short hairpin RNAs  
Construction of shRNA triggers as cassettes with the tet operator-H1 promoter fusion (tH1), 
facilitates the rapid screening for functional shRNA molecules in the pDONR vector prior to 
their transfer into the LV backbone. A panel of five 21-mer short hairpin sequences were 
designed to knockdown expression of human FOXP3 (Invitrogen BLOCK-iT RNAi 
designer). The gateway adaptor tailed tH1-shRNA cassettes generated by a two-step PCR 
reaction (Fig 1b) were inserted into a pDONR vector and sequenced. To screen for functional 
shRNA triggers, HEK293T cells were transiently co-transfected with vectors constitutively 
expressing the short hairpin RNAs (pDONR-shRNA) and the reporter vector Psi (ψ) check 
2™, Promega Corp containing FOXP3 (Psi-check-FOXP3). Functional shRNA triggers were 
then identified by a reduction in Renilla activity from the Psi-check-FOXP3 reporter. To 
confirm on-target specificity of our short-hairpin sequences, a control β-catenin reporter 
vector (Psi-check-β-cat) and a validated β-catenin short hairpin RNA (sh-β-cat) [40] were 
used in all experiments.  
Screening of the predicted FOXP3 shRNA targeting sequences identified one trigger, sh-
1355, that substantially reduced (≈ 40% knockdown) renilla activity of the Psi-check-FOXP3 
reporter compared with cells transfected with the reporter alone. No significant reduction in 
renilla activity was observed in cells co-transfected with Psi-check-FOXP3 and the sh-485, 
sh-767 or sh-981 expression vectors, while sh-1289, intriguingly, led to increased FOXP3 
expression (60% higher) (means of triplicate samples and representative of >3 experiments) 
(Fig 2a). On target specificity was confirmed in cells co-transfected with the β-catenin 
reporter vector (Psi-check-β-catenin) and the short-hairpin β-catenin (sh-βcat), where 
expression was significantly reduced (80% knockdown) compared with cells transfected with 
Psi-check-β-catenin alone. In contrast, no significant knockdown of renilla activity was 
observed in cells co-transfected with sh-1355 and the Psi-check-β-catenin reporter vector or 
in cells co-transfected with sh-Cat and Psi-check-FOXP3 reporter. This screening strategy 
allowed rapid identification a single short hairpin RNA sequence (sh-1355) able to 
specifically knockdown expression of FOXP3.   
 
Conditional regulation of target genes  
Next, we wished to demonstrate Doxycyline-regulated knockdown of our target genes. HEK 
293T cells transduced with plvTsh-1355 and plvTsh-cat were then transiently transfected 
with the Psi-check reporter constructs (Psi-check-FOXP3 or Psi-check-catenin) and 
Doxycyline (Dox) was added (1μg/ml) to de-repress shRNA transcription. Knockdown of the 
reporter genes was monitored by luciferase assay after 48hr. Efficient and specific Dox-
dependent knockdown of the reporter gene activity was observed for both FOXP3 and -
catenin (Fig 2b). In the absence of Dox, cells transduced with LV-T-sh-1355 virus and 
transfected with FOXP3 reporter vector (Psi-check-FOXP3) showed levels of renilla activity 
comparable with that in cells transfected with the Psi-check-FOXP3 alone (data not shown). 
However, addition of Dox (1μg/ml) substantially reduced FOXP3 expression (>70% 
knockdown) (Fig. 2b). In contrast, no change in renilla activity was observed from the β-
catenin expression construct in cells transduced with plv-T-sh-1355 virus either in the 
absence or presence of Dox, indicating that sh-1355 activity is specific. This result also 
indicates that addition of Dox itself had no net effect on expression of the target gene. Target 
specific and Dox inducible knockdown was also observed with the plv-T-shcat transduced 
cells transfected with Psi-check-catenin. Similar results were observed in the Jurkat T cell 
line and NIH3T3 cells for the sh-cat vector (not shown).  
 
Lentivirally delivered FOXP3 is conditionally regulated by sh-1355 in Jurkat T cells.  
The previous experiments have shown that short hairpin RNAs could down-regulate renilla 
activity from a hybrid mRNA containing FOXP3 or  catenin sequences within its 3′ UTR. In 
this mRNA the target gene sequences are not translated. We therefore wished to determine 
whether sh-1355 could conditionally down regulate the intact FOXP3 mRNA.  To do this 
Jurkat cells, which do not express endogenous FOXP3, were transduced with a lentivirus 
expressing FOXP3 from the EF1a promoter (plvEIG-FP3) and GFP from an IRES. Cells 
were sorted by flow cytometry, into a population with the highest GFP
+
 expression (top 5%), 
as compared with all GFP
+ 
cells (pooled population) (Fig.3a). We confirmed that cells with 
the highest GFP fluorescence also exhibited the highest levels of FOXP3 expression by 
intracellular staining (Fig. 3b), suggesting that the IRES driven reporter was a robust marker 
of expression of the target gene in plvEIG-FOXP3. The sorted population of plvEIG-FOXP3 
cells (top5% GFP
+
) were then transduced a second time (super-infected) with plv-T-sh-1355 
lentivirus. As the levels of GFP in the super infected cells were significantly higher than the 
single transduced cells (Fig. 3c), a simple gating strategy was used to analyse FOXP3 
expression levels in cells with the highest MFI for GFP. Cells were treated with Dox 
(1μg/ml) for 48hr, stained intracellularly and then analysed by flow cytometry for FOXP3 
expression.  We observed that FOXP3 levels in cells transduced with both plvEIG-FOXP3 
and plv-T-sh-1355 cultured in the absence of Dox was very similar to that observed in cells 
transduced with plvEIG-FOXP3 alone (Fig. 4a). However, when Dox was added to the 
culture medium, FOXP3 expression in the double transduced cells was significantly reduced, 
approaching the background levels of staining observed in cells not expressing FOXP3 (Fig. 
4a). This result indicated that plv-T-sh-1355 down regulated plvEIG-FOXP3 in a Dox-
dependent manner in Jurkat populations expressing high levels of FOXP3. Real time PCR 
confirmed that FOXP3 mRNA expression was similarly down regulated (Fig. 4b). The 
comparable levels of FOXP3 observed in cells transduced with plvEIG-FOXP3 and cells 
transduced with both plvEIG-FOXP3 and plv-T-sh-1355 cultured in the absence of Dox, is 
consistent with the tight regulation of sh-1355 transcription by the Trex protein in the absence 
of de-repression by Dox. This was confirmed by highly sensitive stem-loop RT PCR analysis 
of the expression of the plvTsh1355 shRNA itself, showing no product in  empty Jurkat cells 
or Jurkat cells transduced with plvTsh1355 in the absence of Dox, but significant sh1355 
product when the Jurkats transduced with plvTsh1355 were cultured in the presence of Dox 
(Fig 4c). 
 
Regulation of FOXP3 in primary human T regs 
 
In order to test the broad scope of this lentiviral vector, we isolated primary human cord 




) and transduced them with plv-T-sh-1355 viral supernatant (25x 
concentrated). Transduced cells (33.5% mean transduction efficiency, n=2) were then 







cells were then cultured in the absence or presence of 
Dox (1µg/ml) for 48hr and subsequently stained intracellularly and analysed by flow 
cytometry for FOXP3 expression. We observed that FOXP3 expression in T reg cells 
transduced with plv-T-sh-1355 cultured in the absence of Dox, was similar to FOXP3 
expression in non-transduced cells in the absence or presence of Dox (not shown). This result 
indicates that Dox has no non-specific effects on FOXP3 expression in non-transduced cells 
and also, importantly, that plv-T-sh-1355 is not leaky in the absence of Dox. When Dox was 
added to the culture medium of T reg plv-T-sh-1355 cells, FOXP3 expression was reduced by 
36.6% (mean fluorescence intensity was reduced from 416 to 340 -/+ Dox respectively) 
compared with T reg plv-T-sh-1355 cells cultured in the absence of Dox (Fig. 4d). These 
results show that plv-T-sh-1355 conditionally down regulates the expression of endogenous 
FOXP3 in human Treg cells in the presence of Dox. 
 
Activation of short hairpin is both sensitive and rapid. 
 A concentration curve to determine the kinetics of Dox induction of sh-1355 activity to 
knockdown expression of FOXP3 was then generated. The results of this experiment showed 
that the concentration of Dox routinely used, 1g/ml, far exceeds that which led to maximal 
FOXP3 knockdown (between 20-40% FOXP3 remaining). At a Dox concentration of 
10ng/ml FOXP3 expression was reduced to ≈ 40% of that expressed in non-Dox treated cells 
(Fig. 5a) indicating the sensitivity of the system. Likewise, using SL-RT PCR, we observed 
no plvTsh1355 shRNA in the absence of Dox but robust expression in the presence of just 
10ng/ml of Dox, (Fig. 5b) confirming the exquisite sensitivity of the system. Activation of 
the short hairpin was also very rapid. In the experiments described here, cells were routinely 
treated with Dox for 48hrs prior to evaluating knockdown of FOXP3 expression, but we 
observed partial knockdown of FOXP3 as early as 12 hours after addition of Dox (68% 
FOXP3 remaining) and maximal knockdown of FOXP3 protein by 24 hours 22 % FOXP3 
remained, compared with non-Dox treated cells (Fig 5c).    
 
Gene regulation is robust and reversible.   
Having shown that target gene (FOXP3) expression can be significantly down-regulated in a 
Dox-dependent manner by lentiviral sh-1355, we next wanted to test the reversibility of the 
drug-induced knockdown of FOXP3 by performing a washout experiment. Jurkat cells 
expressing high levels of FOXP3 from plvEIG-FP3 and super-infected with plv-T-sh-1355 
were cultured in the presence or absence of Dox (1μg/ml) for 48hr. After collecting an aliquot 
of cells for analysis, the remaining cells were washed and returned to culture. Over the next 
120 hours, cells were collected every 24hrs or 48hrs followed by the re-addition of Dox at 
120 hours. As seen previously, FOXP3 expression was reduced to ≈20% of original levels 
after incubation with Dox (1μg/ml) for 48 hours (Fig.5d). After washout of Dox the level of 
FOXP3 expression remained at ≈ 20% for the next 48hr, but increased at each time point 
thereafter until FOXP3 had returned to almost pre-knockdown levels (≈ 90%) by 120 hours 
post-Dox removal. This result shows that drug-induced knockdown of FOXP3 is efficient and 
reversible. To  further test the robustness of the system, after the 120hr time point Dox 
(1μg/ml) was added back and the cells were incubated for a further 48hr. FOXP3 expression 
dropped back down to 20% of original levels (Fig. 5d). FOXP3 expression in cells 
continuously cultured in Dox for 120hr remained very low (3.8% of non-treated cells, (* on 
Fig. 5d) indicating that Dox-induced activation of the short hairpin is robust and prolonged. 
In all cases FOXP3 mRNA levels followed the same expression pattern (Fig. 5e). Over the 
course of the washout experiment, plvTsh1355 shRNA expression exactly mirrors expression 
of FOXP3. Expression of this RNA was high after 48hrs of Dox, but had diminished to near 
background levels after 120hrs washout. plvTsh1355 shRNA levels increased once more 
when Dox was added back to the cells. These results indicate that as the Dox is washed out, 
plvTsh1355 is concomitantly switched off and FOXP3 expression is de-repressed (Fig. 5f, g).  
  
Validation of reversible tet regulated gene ablation in breast cancer cells 
To rigorously establish the utility and reversibility of the vector, we chose to target an 
endogenous cellular gene, the oncogene MYB in the breast cancer cell line MCF7. When a 
pre-validated MYB specific shRNA or a scrambled shRNA [35] were delivered stably into the 
MCF7 cells, no impact on viability or growth characteristics was seen in the absence of Dox, 
as measured in a proliferation assay. However, when Dox was added to the culture at 1ug/ml, 
a significant reduction in growth and proliferation was observed only in the plv-T-sh-Myb 
transduced cells.  When Dox was left on the cells for 5 days a stable gene silencing effect was 
observed both at the level of protein expression and proliferation. This growth suppression 
was reversible, as demonstrated by washout on day 5 and restoration of growth kinetics.  
Furthermore in the sh-Myb line only, the growth inhibition could be re-established by a 
second Dox treatment on day 7 resulting in growth arrest for a second time in the same 
culture (Fig. 6a). The impact of the sh-Myb construct on MYB protein levels was confirmed 
by western blot analysis of the parent cell line, the cell line transduced with sh-Myb, and two 
controls where the cells were transduced with a scrambled shRNA (sh-SCR) or transduced 
with an empty lentiviral vector. In the plv-T-sh-Myb transduced MCF7 cells in the absence of 
Dox, the levels of Myb were comparable with the parent cells or the two controls. MYB was 





The main goal of this study was to build a simple, efficient system with which to 
study gene function, and we chose two genes to model this.  Conditional gene knockdown 
has the potential to be a powerful tool, with short hairpin RNAs emerging as a highly 
effective and relatively straightforward mechanism to achieve this goal. However, for this 
technology to reach its full potential safe, efficient and tightly regulated delivery systems 
need to be further developed. A system that allows regulated control of gene expression 
(including full reversibility) has huge advantages over systems that rely on absolute knockout 
or Cre-mediated excision [9, 41] potentially overcoming issues including lethality. It also 
allows knock-down in the appropriate temporal- or stimulus- specific manner. Critically, 
developing such tools allows for the controlled manipulation of gene-expression in a variety 
of primary cell types and diverse organisms, rather than being restricted to mice.  
Additionally, for a system to be robust, particularly for an in vivo model, manipulation of 
gene expression should also be enduring.   
There have been many advances in the design of gene delivery systems, with 
lentiviruses emerging as a relatively safe system of delivery [42]. We have based the vectors 
described herein on the third generation self-inactivating lentiviral vectors first described and 
shared by Trono et al [10, 43, 44]  and modified by us [12]. We, and others, have 
demonstrated that these lentiviral vectors have improved transduction efficiency, function 
and specificity, particularly into primary cells [45] and are also well tolerated in vivo [15, 46-
48] making them ideal for in vivo studies.  We chose to combine the shRNA and regulatory 
elements into a single vector as we felt that it is less practical to perform multiple 
transductions or to generate clones when targeting rare primary cells or using in vivo models.  
By utilising Gateway® recombination technology we are able to rapidly screen potential 
short hairpins before the production of lentiviral particles. This is of potential benefit as there 
are still persistent problems with short hairpin design, leading to inefficient knockdown of the 
target gene, and thus requiring a number of targeting sequences to be tested for each gene.  
Screening a bank of potential short hairpin RNAs in this way revealed that one sequence out 
of five was able to knockdown target gene expression in a highly specific way.  
 
In this paper we describe a single lentiviral vector capable of delivering tightly 
regulated Dox responsive knockdown of target genes as shown by the regulated knockdown 
of two different genes, FOXP3 and MYB using single short hairpin RNAs delivered into 
several different cell lines (HEK293T, Jurkat and MCF7). We also demonstrate regulated 
knockdown of endogenous FOXP3 in primary human T reg cells.  In contrast with the 
findings of Brake et al, who observed a substantial loss of shRNA activity in transduced cells 
[6], we observed efficient knockdown of target genes in either transfected or transduced cells.  
Throughout our experiments we observed significant knockdown of target genes 
(FOXP3 60-95%, -catenin 80% and MYB ~80% knockdown respectively) indicating 
efficient expression and processing of the short hairpin cassettes. This suggests that sufficient 
shRNA molecules can be produced from a single copy of the tet-H1 promoter shRNA 
cassette in the viral backbone. We obtained high levels of FOXP3 knockdown using an 
MOI=1 in cell lines (MOI= 25 in primary human T regs) compared with others who have had 
to use high viral titres or isolated cell clones to obtain robust target knockdown by short 
hairpin RNAs (summarised in [7]) This compares favourably with results using multiple 
copies of the short hairpin to achieve durable target gene knockdown [5, 6]. Significantly, the 
short hairpin RNA delivery vector plv-T-sh described here appears not to be susceptible to 
inactivating mutations [5] as demonstrated by the finding that MCF7 transduced with a 
lentiviral construct encoding a validated MYB shRNA Gonda et al [35] retains the ability to 
knockdown MYB oncogene levels even after prolonged culture in the absence of Dox. 
Importantly, in the absence of Dox the tet-H1 promoter appears to be tightly regulated 
by the repressor protein, with little evidence of leakiness. Not only was FOXP3 expression in 
Jurkat cells transduced with plv-T-sh-1355, when cultured in the absence of Dox, 
indistinguishable from that in parental cells expressing FOXP3 alone, but importantly plv-T-
sh-1355 RNA was only detected (using the highly sensitive SL-RT-PCR technique) in cells 
treated with Dox. Similar observations were seen in MCF7 cells transduced with plv-T-
shMyb and importantly in the primary human Treg cells transduced with plv-T-sh-1355 to 
knockdown endogenous FOXP3. This has been a hurdle in the development of inducible 
short hairpin RNA technologies where leakiness of shRNA expression has been observed in 
both transfected and transduced cells [8]. 
  In experiments examining the kinetics of shRNAi induction, we show that this 
knockdown is both sensitive and rapid. For example, plv-T-sh-1355 RNA was induced using 
just 10ng/ml Dox and FOXP3 protein expression itself could be reduced in the presence of 
10ng/ml Dox, 100x lower concentrations of Dox than routinely used, with ≈60% knockdown 
of FOXP3 obtained and maximal repression occurring from 25ng/ml of Dox onwards. This 
may be useful for in vivo experiments where systemic administration of Dox is required.  
Secondly, following induction by Dox, de-repression of the Tet-H1 promoter-shRNA 
cassette, initiation of transcription and processing of the short hairpin must be rapid, since we 
observe partial knockdown of FOXP3 protein as early as 12 hours (68% FOXP3 remaining) 
and maximal knockdown of FOXP3 by 24 hours (22 % FOXP3 remaining) compared with 
non-Dox treated cells. This compares favourably with other recently developed systems in 
which prolonged exposures to Dox (5 and 8 days) were required for maximal knockdown at 
the protein level [2, 8]. One of the major strengths of our system is that compared with those 
of others, our system is fully and quickly reversible even when using high concentrations of 
Dox.. Additionally wash out of the Dox resulted in loss of the plv-T-sh-1355 RNA with the 
concomitant gain of FOXP3. Others show reversibility but this is often incomplete or 
relatively slow and insensitive [33, 34]. 
The vector described in this paper provides a simple, single vector system that is 
quickly and strongly inducible and additionally, fully reversible. We have carried out 
carefully analysed kinetics quantitating all of our results with respect to appropriate controls 
to show convincingly the system described here is an advance on systems currently available. 
This system offers not only a valuable tool to study gene function, but also as a tool for 
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Figure Legends.   
 
Figure1. 
A single lentiviral expression vector for drug-inducible knockdown of FOXP3. 
(1a) A diagrammatic representation of the lentiviral vector design. plvEIG lentiviral vector 
provides the backbone for this system. The short hairpin expression cassette (Tetracycline 
mini operon fused to the H1 promoter followed by the target stem loop and a terminator, pT) 
is inserted via Gateway recombination downstream of the packaging signal.  An EF1a 
promoter drives transcription of the TRex™ repression cassette and an IRES is inserted 
upstream of a GFP marker.  (1b) Schematic representation of the PCR cloning strategy used 
to generate the short hairpin cassettes which are then recombined into the gateway vectors.  
 
Figure 2. 
A short hairpin sequence is able to specifically and inducibly knockdown expression of 
FOXP3. 
(2a) HEK293T cells were transiently co-transfected with pDONR vectors containing one of 
five short hairpin sequences ( sh-1355, sh-485, sh-1289, sh-767, sh-981) or control short 
hairpin; sh- ß catenin (sh-ß cat) and also with  the FOXP3 reporter vector (   ) or ß-catenin (ß 
cat) control reporter (   ). (2b) HEK293T cells were transfected with ß-catenin control 
reporter vector and transduced with plvtsh-cat (   ), or with plvTsh-1355(   ) or transfected 
with the FOXP3 reporter vector and transduced with plvtsh-1355 (   ). Cells were then 
incubated – or + Dox.  Chart labels denote the vector with which the cells are transfected 
(abbreviated to FOXP3 or ß-cat), followed by the lentiviral vector (abbreviated to sh-1355 or 
sh- ß-cat). Results are mean +SD expressed relative to the firefly luciferase control (n=3). 
 
Figure 3 Isolation of Jurkat cell lines expressing plvEIG-FOXP3 and plv-T-sh1135. 
(3a) Jurkat cells were transduced with plvEIG-FOXP3 viruses and sorted based on the 
intensity of GFP fluorescence. Frequency histogram shows the top 5% GFP
+
 (     ) isolated 
from the pooled population of GFP
+
 cells (     ) and GFP
- 
cells (      ). (3b) Frequency 
histogram shows the FOXP3 expression in the same sorted populations of GFP
+
 cells. (3c) 
Frequency histogram shows the GFP levels in untransduced Jurkat cells (....), Top5% 
FOXP3 expressing cells  (      )  and FOXP3 +ve cells super-infected with plv-T-sh1135 (     ). 
Since both of these lentiviral vectors express GFP, cells double transduced with plv-T-sh1355 
and plvEIF-FOXP3 were isolated by gating on bright fluorescent GFP
+
 signal, indicating the 
presence of both GFP
+
 lentiviral vectors. 
 
Figure 4 Conditional regulation of FOXP3 expression in Jurkat cells and human Treg. 
(4a) Non-transduced Jurkat cells, cells expressing plvEIG-FOXP3 alone (top 5%) and cells 
co-expressing plvEIG-FOXP3 and plv-T-sh-1355 were cultured in the absence or in the 
presence of Dox (1 µg/ml) for 48hr. The frequency histogram shows intracellular FOXP3 
expression in un-transduced Jurkat cells (....), cells expressing plvEIG-FOXP3 (top 5%) (   ) 
and cells expressing plvEIG-FOXP3 and plv-T-sh1355, in the presence (     ) or absence (    ) 
of Dox (1µg/ml).  (4b) FOXP3 mRNA expression levels were determined by RT PCR 
showing FOXP3 expression in non-transduced Jurkat cells, cells expressing plvEIG-FOXP3 
(top 5%) and cells expressing plvEIG-FOXP3 and plv-T-sh-1355, in the presence (     ) or 
absence (    ) of Dox (1µg/ml). (4c) plv-T-sh-1355 RNA expression was determined using 
SL-RT-PCR. Amplicons from semi-quantitative SL-RT-PCR were separated using 3% 
agarose. plv-T-sh-1355 and Hprt-1 RNA expression in non-transduced Jurkat cells, cells 
expressing plvEIG-FOXP3 and cells expressing plvEIG-FOXP3 and plv-T-sh-1355, in the 
presence and absence of Dox are shown. (4d) Isolated human T regs transduced with plv-T-
sh-1355 were cultured in the presence (     ) or absence (     ) of Dox for 48 hr. Cells were 
stained intracellularly with PEα hu FOXP3 antibody.  
 
Figure 5. Activation of the short hairpin is sensitive, rapid and reversible. 
(5a) Jurkat cells transduced with both plvEIG-FOXP3 and plv-T-sh-1355 were cultured in the 
presence of increasing concentrations of Dox for 48hr, and intracellular FOXP3 expression 
determined by flow cytometry. (5b) plv-T-sh-1355 and control Hprt-1 RNA expression were 
determined using SL-RT-PCR. Amplicons from semi-quantitative SL-RT-PCR were 
separated using 3% agarose. (5c) Jurkat cells transduced with both plvEIG-FOXP3 and plv-
T-sh-1355 were cultured in the presence of Dox (1μg/ml) and FOXP3 expression levels 
analysed over time. (5d) Jurkat cells transduced with both plvEIG-FOXP3 (top5%) and plv-
T-sh-1355 were cultured in the presence or absence of Dox (1µg/ml) for 48hr.  After FOXP3 
measurement, the remaining cells were washed 2 times and returned to culture (labelled 0hr).   
At the times indicated cells were removed for quantification.  FOXP3 expression in cells 
transduced with plvT-sh1355 was determined by expressing MFI from cells in the absence of 
Dox relative to MFI in cells cultured in the presence of Dox. (5e) Relative FOXP3 mRNA 
expression for the cells was determined by calculating FOXP3 mRNA expression from cells 
cultured in the presence of Dox, relative to that in cells cultured in the absence of Dox.  (5f) 
plv-T-sh-1355 RNA expression was determined using SL-RT-PCR. Ct values for plv-T-sh-
1355 RNA were normalised with respect to Ct values for control Hprt-1 and plotted.  (5g) 
Amplicons from semi-quantitative SL-RT-PCR were separated using 3% agarose.  
 
Figure 6. 
 Validation of reversible gene silencing using an endogenous target gene, MYB 
(6a) The Myb dependant growth of the MCF7 cell line was confirmed by lentiviral delivery 
of a validated shMyb construct (black lines). Cells were cultured –Dox (       ), + Dox (       ), 
after a single washout (  ), or washout and re-addition of dox (         ).  Cells transduced with 
a scrambled sh control (grey dashed lines) were also treated – Dox (       ), or + Dox (      ). 
(6b) The on target effects of the lentiviral shMyb were confirmed by western blot (upper 
panel), showing cells -, + Dox, after washout and after add back of Dox.  1ug/ml Dox used 
for induction. Controls with the scrambled sh and an empty vector are shown.  Loading 











Figure 3a)    Figure 3b)    Figure 3c) 
 















Figure 5a)      Figure 5b) 
 









Figure 5d)      Figure 5e) 
 
 
 
 
 
 
 
Figure 5f,g 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 6a, 
 
 
Figure 6b) 
 
 
 
 
 
